HOME
LUPIN FOUNDATION
CAREERS Careers Overview Life at Lupin Campus Connect Learning & Development Current Openings P.L.E.D.G.E.
CONTACT US Contact Us Global Offices Partner With Us Lupin for Suppliers GST Information

EUROPE

Lupin’s Europe business recorded a growth of 13% with sales of Rs.6,414 million during the year.

The key contributors to growth include the portfolio expansion of Hormosan Pharma, our German subsidiary, new product launches and scaling NaMuscla across U.K., Germany and France. During the year, Hormosan entered into a partnership with Eli Lilly to promote their migraine product Emgality further strengthening Hormosan’s position as a market leader in the cluster headache and migraine segment. In the U.K., we also launched Valproate Semisodium and several ARVs.